Pediatrix Medical Group, Inc. (NYSE:MD) Given Average Rating of “Hold” by Brokerages

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have received an average recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat reports. Five research analysts have rated the stock with a hold rating and one has issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $19.80.

MD has been the topic of several recent research reports. Weiss Ratings reiterated a “hold (c+)” rating on shares of Pediatrix Medical Group in a research report on Monday, December 29th. UBS Group dropped their price target on shares of Pediatrix Medical Group from $23.00 to $22.00 and set a “neutral” rating on the stock in a research note on Tuesday, February 24th. Deutsche Bank Aktiengesellschaft set a $19.00 price target on Pediatrix Medical Group in a report on Friday, February 20th. Zacks Research lowered Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a report on Friday, January 23rd. Finally, Truist Financial lowered their target price on Pediatrix Medical Group from $24.00 to $21.00 and set a “hold” rating on the stock in a research report on Thursday, February 19th.

Pediatrix Medical Group Price Performance

Shares of NYSE MD opened at $19.79 on Monday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.66 and a quick ratio of 1.66. The firm has a market capitalization of $1.64 billion, a PE ratio of 10.20 and a beta of 0.79. Pediatrix Medical Group has a 1-year low of $11.84 and a 1-year high of $24.99. The business’s fifty day moving average price is $21.11 and its two-hundred day moving average price is $19.95.

Pediatrix Medical Group (NYSE:MD) last announced its quarterly earnings results on Thursday, February 19th. The company reported $0.50 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.53 by ($0.03). The firm had revenue of $493.77 million for the quarter, compared to analyst estimates of $486.23 million. Pediatrix Medical Group had a net margin of 8.64% and a return on equity of 19.59%. The business’s revenue was down 1.7% compared to the same quarter last year. During the same period last year, the firm posted $0.51 EPS. On average, research analysts expect that Pediatrix Medical Group will post 1.38 EPS for the current year.

Insider Activity

In other news, CEO Mark S. Ordan sold 23,000 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $22.41, for a total value of $515,430.00. Following the completion of the transaction, the chief executive officer owned 302,805 shares of the company’s stock, valued at approximately $6,785,860.05. This represents a 7.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Insiders own 0.90% of the company’s stock.

Institutional Investors Weigh In On Pediatrix Medical Group

A number of hedge funds and other institutional investors have recently modified their holdings of MD. Invesco Ltd. grew its position in Pediatrix Medical Group by 24.4% in the 4th quarter. Invesco Ltd. now owns 1,090,655 shares of the company’s stock valued at $23,329,000 after buying an additional 213,636 shares in the last quarter. State of Tennessee Department of Treasury raised its holdings in Pediatrix Medical Group by 2.8% during the fourth quarter. State of Tennessee Department of Treasury now owns 46,016 shares of the company’s stock worth $984,000 after purchasing an additional 1,246 shares in the last quarter. EP Wealth Advisors LLC acquired a new stake in shares of Pediatrix Medical Group in the fourth quarter valued at $472,000. Mackenzie Financial Corp lifted its stake in Pediatrix Medical Group by 35.7% during the fourth quarter. Mackenzie Financial Corp now owns 55,150 shares of the company’s stock valued at $1,201,000 after purchasing an additional 14,502 shares during the last quarter. Finally, Empowered Funds LLC lifted its position in shares of Pediatrix Medical Group by 17.8% during the 4th quarter. Empowered Funds LLC now owns 622,380 shares of the company’s stock valued at $13,313,000 after acquiring an additional 93,833 shares during the last quarter. 97.71% of the stock is currently owned by institutional investors.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.